Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday

Cue Biopharma (NASDAQ:CUE) is expected to post its quarterly earnings results on Wednesday, March 26th. Analysts expect Cue Biopharma to post earnings of ($0.15) per share and revenue of $1.70 million for the quarter.

Cue Biopharma Price Performance

Shares of Cue Biopharma stock opened at $0.98 on Monday. The business’s fifty day moving average price is $1.25 and its 200 day moving average price is $1.17. Cue Biopharma has a twelve month low of $0.45 and a twelve month high of $2.26. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $62.37 million, a P/E ratio of -1.09 and a beta of 1.88.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.